259 related articles for article (PubMed ID: 18400375)
1. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
Cao C; Lu S; Sowa A; Kivlin R; Amaral A; Chu W; Yang H; Di W; Wan Y
Cancer Lett; 2008 Aug; 266(2):249-62. PubMed ID: 18400375
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
[TBL] [Abstract][Full Text] [Related]
3. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells.
Hsieh CY; Tsai PC; Tseng CH; Chen YL; Chang LS; Lin SR
Toxicol In Vitro; 2013 Feb; 27(1):1-10. PubMed ID: 23064031
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
[TBL] [Abstract][Full Text] [Related]
6. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
Britain CM; Holdbrooks AT; Anderson JC; Willey CD; Bellis SL
J Ovarian Res; 2018 Feb; 11(1):12. PubMed ID: 29402301
[TBL] [Abstract][Full Text] [Related]
7. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
8. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
Shien T; Doihara H; Hara H; Takahashi H; Yoshitomi S; Taira N; Ishibe Y; Teramoto J; Aoe M; Shimizu N
Breast Cancer; 2004; 11(4):367-73. PubMed ID: 15604992
[TBL] [Abstract][Full Text] [Related]
9. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
10. Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors.
Koumangoye RB; Nangami GN; Thompson PD; Agboto VK; Ochieng J; Sakwe AM
Mol Cancer; 2013 Dec; 12(1):167. PubMed ID: 24354805
[TBL] [Abstract][Full Text] [Related]
11. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract][Full Text] [Related]
12. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
13. EGFR is dispensable for c-Met-mediated proliferation and survival activities in mouse adult liver oval cells.
Martínez-Palacián A; Del Castillo G; Herrera B; Fernández M; Roncero C; Fabregat I; Sánchez A
Cell Signal; 2012 Feb; 24(2):505-513. PubMed ID: 22001397
[TBL] [Abstract][Full Text] [Related]
14. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.
Dong Y; He Y; de Boer L; Stack MS; Lumley JW; Clements JA; Hooper JD
J Biol Chem; 2012 Mar; 287(13):9792-9803. PubMed ID: 22315226
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.
Dajani OF; Meisdalen K; Guren TK; Aasrum M; Tveteraas IH; Lilleby P; Thoresen GH; Sandnes D; Christoffersen T
J Cell Physiol; 2008 Feb; 214(2):371-80. PubMed ID: 17654493
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.
Yu Y; Zhang M; Zhang X; Cai Q; Hong S; Jiang W; Xu C
J Hematol Oncol; 2014 May; 7():39. PubMed ID: 24886678
[TBL] [Abstract][Full Text] [Related]
17. EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Ren J; Bollu LR; Su F; Gao G; Xu L; Huang WC; Hung MC; Weihua Z
Prostate; 2013 Sep; 73(13):1453-61. PubMed ID: 23765757
[TBL] [Abstract][Full Text] [Related]
18. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells.
Vacca F; Bagnato A; Catt KJ; Tecce R
Cancer Res; 2000 Sep; 60(18):5310-7. PubMed ID: 11016663
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.
Bremer E; Samplonius DF; van Genne L; Dijkstra MH; Kroesen BJ; de Leij LF; Helfrich W
J Biol Chem; 2005 Mar; 280(11):10025-33. PubMed ID: 15644326
[TBL] [Abstract][Full Text] [Related]
20. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
